BR9709097A - Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária - Google Patents

Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária

Info

Publication number
BR9709097A
BR9709097A BR9709097A BR9709097A BR9709097A BR 9709097 A BR9709097 A BR 9709097A BR 9709097 A BR9709097 A BR 9709097A BR 9709097 A BR9709097 A BR 9709097A BR 9709097 A BR9709097 A BR 9709097A
Authority
BR
Brazil
Prior art keywords
treatment
cyclooxygenase
treat
pharmaceutical composition
unit dose
Prior art date
Application number
BR9709097A
Other languages
English (en)
Inventor
Bruno Hancock
Conrad Winters
Barry Gertz
Elliot Ehrich
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9709097(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of BR9709097A publication Critical patent/BR9709097A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9709097A 1996-05-17 1997-05-13 Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária BR9709097A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
BR9709097A true BR9709097A (pt) 1999-08-03

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709097A BR9709097A (pt) 1996-05-17 1997-05-13 Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária

Country Status (28)

Country Link
US (1) US6063811A (pt)
EP (1) EP0910368A1 (pt)
JP (1) JPH11512754A (pt)
KR (1) KR100373622B1 (pt)
CN (1) CN1140267C (pt)
AR (1) AR012014A1 (pt)
AU (1) AU3004997A (pt)
BG (1) BG103000A (pt)
BR (1) BR9709097A (pt)
CA (1) CA2254061C (pt)
CO (1) CO5050370A1 (pt)
CZ (1) CZ291463B6 (pt)
DZ (1) DZ2200A1 (pt)
EA (1) EA001596B1 (pt)
EE (1) EE03746B1 (pt)
HR (1) HRP970262A2 (pt)
HU (1) HUP9902889A3 (pt)
ID (1) ID16921A (pt)
IL (1) IL126899A (pt)
IS (1) IS4891A (pt)
MY (1) MY116201A (pt)
NO (1) NO985342D0 (pt)
NZ (1) NZ332670A (pt)
PE (1) PE66998A1 (pt)
PL (1) PL188649B1 (pt)
SK (1) SK284330B6 (pt)
TR (1) TR199802345T2 (pt)
WO (1) WO1997044028A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506024A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1239856A1 (en) * 1999-12-22 2002-09-18 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
EA011309B1 (ru) 2000-06-13 2009-02-27 Вайет Составы для ослабления боли, содержащие целекоксиб
EP1309315B1 (en) * 2000-08-18 2006-06-14 Pharmacia Corporation Rapidly disintegrating oral formulation of valdecoxib
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1423114A4 (en) * 2001-05-04 2006-05-17 Merck & Co Inc METHOD AND COMPOSITIONS FOR TREATING MIGRAINE
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
PL369298A1 (en) * 2001-09-26 2005-04-18 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions
CA2462881A1 (en) * 2001-10-10 2003-04-17 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by spray drying process
KR20040089654A (ko) * 2002-03-07 2004-10-21 노파르티스 아게 약제학적 조성물
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1995018799A1 (en) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
HK1021623A1 (en) 2000-06-23
HRP970262A2 (en) 1998-06-30
EA001596B1 (ru) 2001-06-25
SK156798A3 (en) 2000-01-18
EP0910368A1 (en) 1999-04-28
EE9800393A (et) 1999-06-15
DZ2200A1 (fr) 2004-06-20
PL188649B1 (pl) 2005-03-31
IS4891A (is) 1998-11-10
KR20000011082A (ko) 2000-02-25
HUP9902889A3 (en) 2002-04-29
CZ291463B6 (cs) 2003-03-12
PL329940A1 (en) 1999-04-26
NO985342L (no) 1998-11-16
IL126899A (en) 2004-03-28
ID16921A (id) 1997-11-20
CA2254061C (en) 2003-12-02
IL126899A0 (en) 1999-09-22
EE03746B1 (et) 2002-06-17
CN1140267C (zh) 2004-03-03
NZ332670A (en) 2000-07-28
CN1225010A (zh) 1999-08-04
CO5050370A1 (es) 2001-06-27
CZ373898A3 (cs) 1999-06-16
AU3004997A (en) 1997-12-09
WO1997044028A1 (en) 1997-11-27
HUP9902889A2 (hu) 2002-01-28
TR199802345T2 (xx) 1999-03-22
PE66998A1 (es) 1998-10-24
SK284330B6 (sk) 2005-01-03
US6063811A (en) 2000-05-16
JPH11512754A (ja) 1999-11-02
CA2254061A1 (en) 1997-11-27
EA199801017A1 (ru) 1999-04-29
NO985342D0 (no) 1998-11-16
KR100373622B1 (ko) 2003-07-12
AR012014A1 (es) 2000-09-27
MY116201A (en) 2003-11-28
BG103000A (en) 1999-09-30

Similar Documents

Publication Publication Date Title
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
BR9710372A (pt) Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase
BR9408478A (pt) Composto composição farmacéutica processos de tratmento de uma doença suscetível ao tratamento com agente anti-inflamatório não esteroidal e de tratamento de doenças medidas pela ciclo-oxigenase, sal farmaceuticamente eficaz e uso de um composto
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
BR9605111A (pt) Formulação de dosagem farmacêutica oral processo para a manufatura de uma formulação de dosagem fixa método para o tratamento de distúrbios com infecções por helicobacter pylori em mamiferos e no ser humano e uso de uma formulação de dosagem
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
BR9509498A (pt) Agente aglutinante uso do mesmo composição farmacêutica e processo para tratamento de uma doença inflamatória autoimune ou uma doença alérgica
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
PT98897A (pt) Processo para a preparacao de novos esteres de pregna-1,4-dieno-3,20-diona-16-17-acetal-21 e suas composicoes aplicaveis no tratamento de condicoes inflamatorias
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
BR9406566A (pt) Composição farmacêutica uso de progesterona e/ou 17 - - estradiol e processo para a fabricação de uma preparação farmacêutica
PT877716E (pt) Composicoes de vidro bioactivo para uso no tratamento de estruturas dentais
FI20115742L (fi) Mometasonifuroaatin käyttö lääkkeen valmistuksessa
BRPI0410260A (pt) composição conjugada para medicamento
FI971440A7 (fi) Sukupuolitauteja vastaan suunnatun formulaation käyttötapa ja tätä sis ältävä koostumus
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
FI944549A7 (fi) Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
CY1108633T1 (el) Κοσμητικη συνθεση βασεως σουκραλφατ και θειικων αλατων χαλκου και ψευδαργυρου
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
EE9800393A (et) Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
BR9611555A (pt) Compostos formulação farmacêutica utilização de um composto processo para tratamento de uma doença obstrutiva reversível das vias aéreas e para preparação do composto

Legal Events

Date Code Title Description
PCP Transfer pending
HKT Transfer or change (deleted)
PC Transfer

Free format text: MERCK FROSST CANADA & CO./MERCK FROSST CANADA & CIE. (CA)

HHT Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Free format text: REFERENCIA: RPI 1502 DE 19/10/1999 E RPI 1512 DE 28/12/1999 - CODIGOS 25.3 E 25.12 ITEM (71)

HKT Transfer or change (deleted)
PC Transfer

Free format text: MERCK FROSST CANADA & CO./MERCK FROSST CANADA & CIE. (CA)

HHT Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Free format text: TRANSFERIDO DE: MERCK FROSST CANADA INC. - REF. RPI 1593 DE 17/07/2001 COD. 25.1 ITEM 71

FM Others concerning applications: unknown petition
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1849 DE 13/06/2006.